Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

CLIO LABORATORIES, LLC

NPI: 1013382431 · LAWRENCEVILLE, GA 30043 · Clinical Medical Laboratory · NPI assigned 12/10/2015

$90K
Total Medicaid Paid
5,977
Total Claims
5,363
Beneficiaries
16
Codes Billed
2018-03
First Month
2019-09
Last Month

Provider Details

Authorized OfficialDIAB, ARAFAT (OWNER)
NPI Enumeration Date12/10/2015

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 4,560 $24K
2019 1,417 $65K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 872 627 $47K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1,019 743 $36K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 137 109 $5K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 244 200 $290.47
81241 304 303 $0.00
81401 304 303 $0.00
81355 305 304 $0.00
81328 304 303 $0.00
81291 304 303 $0.00
81479 Unlisted molecular pathology procedure 324 317 $0.00
81225 311 310 $0.00
81231 305 304 $0.00
81226 329 325 $0.00
81230 305 304 $0.00
81227 306 305 $0.00
81240 304 303 $0.00